Cidara Therapeutics price target raised to $69 from $68 at Guggenheim

Guggenheim raised the firm’s price target on Cidara Therapeutics (CDTX) to $69 from $68 and keeps a Buy rating on the shares. Guggenheim updated its model following Cidara’s recent equity raise and the NAVIGATE Phase 2b data, which provided critical validation of CD388 as a compelling flu prevention option, the analyst tells investors in a research note. A potential BARDA funding decision offers additional upside optionality as early as September 2025, the firm says.